Martin Frotscher (189200)

No ORCID on file · 5 papers in corpus · active 1753-2022

Study types

  • article 3
  • dataset 2

Condition tags

  • endometriosis 4
dataset 2022
Dual Targeting\nof Steroid Sulfatase and 17β-Hydroxysteroid\nDehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential\nTherapeutic Option for the Treatment of Endometriosis
·doi:10.1021/acs.jmedchem.2c00589.s002

A novel approach for the dual inhibition of steroid sulfatase\n(STS)\nand 17β-hydroxysteroid dehydrogenase type 1(17β HSD1)\nby a single drug was explored, starting from in-house 17β HSD1\ninhibitors via masking their phenolic OH group with…

article 2022
Dual Targeting\nof Steroid Sulfatase and 17β-Hydroxysteroid\nDehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential\nTherapeutic Option for the Treatment of Endometriosis
·doi:10.1021/acs.jmedchem.2c00589.s001

A novel approach for the dual inhibition of steroid sulfatase\n(STS)\nand 17β-hydroxysteroid dehydrogenase type 1(17β HSD1)\nby a single drug was explored, starting from in-house 17β HSD1\ninhibitors via masking their phenolic OH group with…

article 2016
Lead Optimization of 17β-HSD1\nInhibitors of\nthe (Hydroxyphenyl)naphthol Sulfonamide Type for the Treatment of\nEndometriosis
·doi:10.1021/jm201735j.s001

The reduction of estrone to estradiol, the most potent\nestrogen\nin human, is catalyzed by 17β-hydroxysteroid dehydrogenase type\n1 (17β-HSD1). A promising approach for the treatment of estrogen-dependent\ndiseases is the reduction of intr…

dataset 1753
Potent Dual\nInhibitors of Steroid Sulfatase and 17β-Hydroxysteroid\nDehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse\nModel
·doi:10.1021/acs.jmedchem.3c00571.s001

Treating estrogen-dependent diseases like endometriosis\nwith drugs\nsuppressing local estrogen activation may be superior to existing\nendocrine therapies. Steroid sulfatase (STS) and 17β-hydroxysteroid\ndehydrogenase type 1 (17β-HSD1) are…

article 1753
Potent Dual\nInhibitors of Steroid Sulfatase and 17β-Hydroxysteroid\nDehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse\nModel
·doi:10.1021/acs.jmedchem.3c00571.s002

Treating estrogen-dependent diseases like endometriosis\nwith drugs\nsuppressing local estrogen activation may be superior to existing\nendocrine therapies. Steroid sulfatase (STS) and 17β-hydroxysteroid\ndehydrogenase type 1 (17β-HSD1) are…